Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Cash & Equivalents: 2021-2024

Historic Cash & Equivalents for Krystal Biotech (KRYS) over the last 4 years, with Dec 2024 value amounting to $344.9 million.

  • Krystal Biotech's Cash & Equivalents rose 4.98% to $392.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $392.6 million, marking a year-over-year increase of 4.98%. This contributed to the annual value of $344.9 million for FY2024, which is 3.76% down from last year.
  • According to the latest figures from FY2024, Krystal Biotech's Cash & Equivalents is $344.9 million, which was down 3.76% from $358.3 million recorded in FY2023.
  • Over the past 5 years, Krystal Biotech's Cash & Equivalents peaked at $358.3 million during FY2023, and registered a low of $161.9 million during FY2022.
  • Over the past 3 years, Krystal Biotech's median Cash & Equivalents value was $344.9 million (recorded in 2024), while the average stood at $288.4 million.
  • In the last 5 years, Krystal Biotech's Cash & Equivalents plummeted by 52.56% in 2022 and then skyrocketed by 121.33% in 2023.
  • Over the past 4 years, Krystal Biotech's Cash & Equivalents (Yearly) stood at $341.2 million in 2021, then crashed by 52.56% to $161.9 million in 2022, then skyrocketed by 121.33% to $358.3 million in 2023, then declined by 3.76% to $344.9 million in 2024.